📊 AI Stock Rating — Summary

Roivant Sciences Ltd. reported a quarterly revenue of approximately $1.57 million with a net income loss of $113.52 million as of September 30, 2025, resulting in an EPS of zero. The company demonstrated a negative free cash flow of $193.51 million. From a growth perspective, Roivant’s revenues remain minimal considering its industry and capital structure. The company is not yet profitable, with significant operating cash outflows reflecting ongoing developmental expenses typical of biotech companies. On the balance sheet, net debt stands at a negative $1.14 billion, indicating a substantial cash reserve relative to its debt, underpinning a robust financial position. Despite the cash burn, Roivant's total assets of approximately $5.06 billion markedly surpass its liabilities. Shareholder returns have been non-existent in the form of dividends or buybacks, but analyst price targets suggesting upside up to $29 suggest optimistic market sentiments. Since the market performance over the past year isn’t available, market reactions will need close observation post-earnings to gauge investor confidence and stock appeal. Analyst sentiment as per the price target consensus toward Roivant remains optimistic although the company's current metrics need analysis for a complete valuation appraisal.

AI Score Breakdown

Revenue Growth — Score: 2/10

Revenue growth remains minimal at $1.57 million with negligible growth recorded. Main drivers include potential R&D advancements yet to translate into sales.

Profitability — Score: 2/10

Current profitability is significantly negative with a net loss of $113.52 million, indicating continued investment without immediate returns.

Cash Flow Quality — Score: 3/10

Negative free cash flow of $193.51 million indicates high cash burn relative to cash inflows. No dividends or buybacks suggest focus on reinvesting cash reserves.

Leverage & Balance Sheet — Score: 7/10

Strong balance sheet with net debt of negative $1.14 billion and total assets significantly exceeding liabilities, indicating financial resilience and liquidity.

Shareholder Returns — Score: 5/10

There are no dividends or buybacks, but positive analyst forecasts indicate potential for capital appreciation. Current price trends are not specified.

Analyst Sentiment & Valuation — Score: 6/10

Analyst price targets up to $29 suggest positive expectations. Current lack of profitability and valuation metrics prevent a definitive valuation comparison.

⚠ AI-generated — informational only, not financial advice.